|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||44.63 - 44.63|
|52-week range||41.08 - 75.81|
|Beta (5Y monthly)||-0.07|
|PE ratio (TTM)||11.11|
|Forward dividend & yield||1.08 (2.58%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||N/A|
Shares in Hikma Pharmaceuticals (LON:HIK) are currently trading at 1,727p, but a key question for investors is how much the current economic uncertainty will a...
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
The London-listed drugmaker now expects revenue from its generics unit to be between $710 million and $750 million for 2022, with core operating margin of around 20%. The revised outlook comes in stark contrast to the company's trading statement last week, when it had forecasted revenue from the business to grow 8% to 10% over 2021 sales of $820 million and predicted core operating margin in the range of 24% to 25%. FTSE 100-listed shares of Hikma, which supplies many generic drugs including pain medications, anaesthetics and sedatives, were down 9.6% at 1,667.5 pence by 0739 GMT and were the biggest loser on the UK blue-chip index.